Drug profile · INN
besifloxacin hydrochloride
BESIVANCE
besifloxacin hydrochloride (BESIVANCE) is a bacterial dna gyrase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — besifloxacin hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
besifloxacin hydrochloride (BESIVANCE) is a bacterial dna gyrase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial DNA gyrase inhibitor
Primary target: Bacterial DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is besifloxacin hydrochloride?
besifloxacin hydrochloride (BESIVANCE) is a bacterial dna gyrase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for besifloxacin hydrochloride?
BESIVANCE is a marketed brand name for besifloxacin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of besifloxacin hydrochloride?
besifloxacin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.